£33.0M
The financing round was led by BGF with participation from new and existing backers to support clinical development.
PhoreMost
PhoreMost develops targeted therapies for cancer and age related conditions.
£33.0MTotal raised
PhoreMost is a British biopharmaceutical company that develops novel therapies for oncology and diseases of ageing using its proprietary SITESEEKER platform.
Categories
Team
CB
Catherine Beech
Chair of Board of Directors
CT
Chris Torrance
CEO
Chris brings operating and leadership experience from his roles as chief executive and founder across life sciences companies. He currently serves as founder and chair at PhoreMost.
LinkedInKO
Katie Odgaard
Media Enquiries Contact